title: The effects of an alpha-2 adrenergic agonist, guanfacine, on rCBF in human cortex in normal controls and subjects with focal epilepsy.
abstract: Alpha-2 noradrenergic agonists may have wide applicability in the treatment of pre-frontal cortex deficits in primates and behavioral dysfunction in man. We have undertaken this study to determine the effect of an alpha-2 agonist, guanfacine, on regional cerebral blood flow (rCBF) in humans. Three subject groups were evaluated: normal controls, subjects with frontal lobe epilepsy (FLE), and subjects with temporal lobe epilepsy (TLE). All underwent a number of PET scans using 15O-water, with half before and half after a single dose of guanfacine. A wide area of increased rCBF was seen in the frontal lobe, maximal at the central region, following guanfacine in controls and subjects with TLE. Smaller areas of decrease in rCBF were seen in the posterior temporal-occipital cortex. In the FLE group a decrease in rCBF was seen in the dorsal prefrontal cortex on the epileptogenic side with only small increases seen in the mid- to anterior temporal perisylvian areas. The ability of alpha-2 agonists to enhance performance of tasks reliant on prefrontal cortex, without improving tasks believed to rely on intact temporal-hippocampal function, may be explained by these results. Epileptogenic zones appear to create both direct and indirect changes in patterns of drug response. Further studies on the cognitive properties of these agents in humans should be encouraged.
authors.affiliation: University of California Los Angeles, Neurology Department, CA, USA. bes5@po.cwru.edu
authors.forename: B E
authors.initials: BE
authors.lastname: Swartz
authors.forename: E
authors.initials: E
authors.lastname: Kovalik
authors.forename: K
authors.initials: K
authors.lastname: Thomas
authors.forename: D
authors.initials: D
authors.lastname: Torgersen
authors.forename: M A
authors.initials: MA
authors.lastname: Mandelkern
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002540:Cerebral Cortex / Q000098:blood supply* / Q000000981:diagnostic imaging / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004828:Epilepsies, Partial / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000523:psychology; D004833:Epilepsy, Temporal Lobe / Q000000981:diagnostic imaging / Q000378:metabolism / Q000523:psychology; D005260:Female; D019788:Fluorodeoxyglucose F18; D016316:Guanfacine / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008570:Memory, Short-Term / Q000187:drug effects; D008875:Middle Aged; D011597:Psychomotor Performance / Q000187:drug effects; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D016316:Guanfacine